Brivaracetam (Briviact®)

The National Health Care Institute has approved a pharmacotherapeutic report for the medicine brivaracetam (Briviact®), whereby they reached the following conclusion. Based on the criteria of the Medicines Reimbursement System (GVS), the National Health Care Institute is of the opinion that brivaracetam is mutually replaceable with levetiracetam and lacosamide, and can therefore be included on List 1A of the GVS in cluster 0N03AXDO V with a standard dose of 100 mg.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.